Total medical devices industry M&A deals in February 2020 worth $189.47m were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 87.5% over the previous month and a drop of 94.3% when compared with the last 12-month average, which stood at $3.34bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $77.04m. At the country level, the US topped the list in terms of deal value at $77.04m.
In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Middle East and Africa.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The top country in terms of M&A deals activity in February 2020 was the US with 15 deals, followed by Germany with two and Israel with two.
In 2020, as of the end of February 2020, medical devices M&A deals worth $1.7bn were announced globally, marking a decrease of 77.9% year on year.
Medical devices industry M&A deals in February 2020: Top deals
The top five medical devices industry M&A deals accounted for 81.9% of the overall value during February 2020.
The combined value of the top five medical devices M&A deals stood at $155.17m, against the overall value of $189.47m recorded for the month.
The top five medical devices industry deals of February 2020 tracked by GlobalData were:
1) Meridian Bioscience’s $54.17m acquisition of Exalenz Bioscience
2) The $40m asset transaction with Icagen by Ligand Pharmaceuticals
3) Zealand Pharma’s $23m acquisition of Valeritas Holdings
4) The $20m acquisition of Maxtec by Halma
5) Orthofix Medical’s asset transaction with WITTENSTEIN intens for $18m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.